Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Inclusion Criteria:

* Pts have baseline evaluations performed ≤14days prior to 1st dose of study drug unless otherwise specified. Written informed consent must be obtained from pt prior to enrollment
* Pts w MG who are presenting in 1st, 2nd or 3rd recurrence or relapse
* Pts may not have tumor biopsy \<1 wk or surgical resection \<2wks
* For stratum of non-EIAED pts, each pt be off all EIAEDs for \>2 wks prior to starting study drug; similarly for stratum of EIAED pts, each pt be on EIAED for \>2 wks prior to starting study drug
* Pts should be on non-increasing dose of steroids for \>7 days prior to obtaining baseline Gd-MRI of brain
* Pts should be on non-increasing dose of steroids for \>7 days prior to starting study drug
* Multifocal disease is eligible
* Age \>18yrs
* Karnofsky Performance Status (KPS) of \>70
* Absolute neutrophil count (ANC) \> 1.0 x 10 9/L
* Hgb\>g/dL
* Platelets\>100 x 10 9/L
* Serum creatinine\<1.5 x upper limit of normal (ULN)/measured 24hr creatinine clearance (CrCl) \>50 milliliters/min/1.73m
* Life ≥12wks
* Written informed consent obtained prior to any screening procedures

Exclusion Criteria:

* Serum bilirubin \>1.5x ULN of reference range
* Serum creatinine \>1.5 x Upper Limit of the Reference Range (ULRR)/CrCl \<50 milliliters/min
* K\<4.0 mmol/L despite supplementation; serum Ca/Mg out of normal range despite supplementation
* alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 x ULRR
* Evidence of severe/uncontrolled systemic disease or any concurrent condition which in Investigator's opinion makes it undesirable for pt to participate in trial or which would jeopardize compliance w protocol
* Clinically significant cardiac event such as myocardial infarction; New York Heart Association (NYHA) classification of heart disease \>2 within 3 months before entry;/presence of cardiac disease that, in opinion of Investigator, increases risk of ventricular arrhythmia or dysfunction; ejection fraction\<50 percent prior to study initiation
* History of arrhythmia-symptomatic/requires treatment/asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded
* Previous history of corrected QT interval (QTc) prolongation as result from other medication that required discontinuation of that medication
* Congenital long QT syndrome/1st degree relative with unexplained sudden death under 40 years
* Presence of left bundle branch block
* QTc with Bazett's correction that is unmeasurable/\>480 msec on screening ECG. If pt has QTc \>480 msec on screening ECG, screen ECG may be repeated twice. Average QTc from 3 screening ECGs must be \<480 msec in order for pt to be eligible for study
* Any concomitant medication that may cause QTc prolongation, induce Torsades de Pointes/induce cytochrome P450 3A4 (CYP3A4) function except for EIAEDs
* Hypertension not controlled by medical therapy
* Currently active diarrhea that may affect ability of pt to absorb study regimen/tolerate diarrhea
* Pregnant/breast feeding
* Previous/current malignancies of other histologies \<1yr, w exception of cervical carcinoma in situ \& adequately treated basal cell/squamous cell carcinoma of skin
* Receipt of any investigational agents within 30 days prior to commencing study treatment unless pt has recovered from all anticipated toxicities of investigational agent
* Last dose of prior chemo discontinued \<4 wks before start of study therapy unless pt has recovered from all anticipated toxicities of chemo
* Last radiation therapy (XRT) \<4wks before start of study therapy, unless pt has recovered from all anticipated toxicities of XRT
* Any unresolved toxicity \> Common Terminology Criteria (CTC) grade 1 from previous anti-cancer therapy
* Previous enrollment/randomization of treatment in present study
* Major surgery \<4 wks/incompletely healed surgical incision before starting study therapy
* Pts who have received prior oral VEGFR, EGFR/PDGFR-directed therapies
* Pts who are taking warfarin sodium